{{Redirect|F5U|the Flying Flapjack|Vought XF5U}}
{{Redirect|Carac|Swiss dessert pastry|Carac (pastry)}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 456480929
| IUPAC_name = 5-Fluoro-1''H'',3''H''-pyrimidine-2,4-dione
| image = Fluorouracil2DACS.svg
| width = 80
| image2 = Fluorouracil3DanZ.gif
| width2 = 100
<!--Clinical data-->
| pronounce = {{IPAc-en|ˌ|f|l|ʊr|oʊ|ˈ|j|ʊr|ə|ˌ|s|ɪ|l}}<ref>{{cite web |title=Fluorouracil – Definition and More from the Free Merriam-Webster Dictionary |url=http://www.merriam-webster.com/dictionary/fluorouracil |accessdate=2014-11-19}}</ref>
| tradename = Adrucil, Carac, Efudex, Efudix, others
| Drugs.com = {{drugs.com|monograph|fluorouracil}}
| MedlinePlus = a682708
| licence_US = Fluorouracil
| pregnancy_AU = D
| pregnancy_category = <br>D (IV), X (topical) <small>([[United States|US]])</small>
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = [[Intravenous therapy|IV]] (infusion or [[wikt:bolus|bolus]]) and topical
<!--Pharmacokinetic data-->
| bioavailability = 28 to 100%
| protein_bound = 8 to 12%
| metabolism = Intracellular and [[liver]] ([[cytochrome P450|CYP]]-mediated)
| elimination_half-life = 16 minutes
| excretion = [[kidney]]
<!--Identifiers-->
| IUPHAR_ligand = 4789
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 51-21-8
| ATC_prefix = L01
| ATC_suffix = BC02
| PubChem = 3385
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00544
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3268
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = U3P01618RT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00584
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 46345
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 185
<!--Chemical data-->
| C=4 | H=3 | F=1 | N=2 | O=2
| molecular_weight = 130.077 g/mol
| smiles = c1c(c(=O)[nH]c(=O)[nH]1)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GHASVSINZRGABV-UHFFFAOYSA-N
| melting_point = 282–283
}}
<!-- Definition and medical uses -->
'''Fluorouracil''' ('''5-FU'''), sold under the brand name '''Adrucil''' among others, is a medication used to treat [[cancer]].<ref name=AHFS2016/> By [[intravenous|injection into a vein]] it is used for [[colon cancer]], [[esophageal cancer]], [[stomach cancer]], [[pancreatic cancer]], [[breast cancer]], and [[cervical cancer]].<ref name=AHFS2016>{{cite web|title=Fluorouracil|url=https://www.drugs.com/monograph/fluorouracil.html|publisher=The American Society of Health-System Pharmacists|accessdate= 8 December 2016}}</ref> As a cream it is used for [[actinic keratosis]] and [[basal cell carcinoma]].<ref name=AHFS2016Top>{{cite web|title=Fluorouracil topical|url=https://www.drugs.com/monograph/fluorouracil-topical.html|publisher=The American Society of Health-System Pharmacists|accessdate= 8 December 2016}}</ref>

<!-- Side effects and mechanism -->
When used by injection most people develop side effects.<ref name=AHFS2016/> Common side effects include inflammation of the mouth, loss of appetite, [[cytopenia|low blood cell counts]], hair loss, and inflammation of the skin.<ref name=AHFS2016/> When used as a cream, irritation at the site of application may occur.<ref name=AHFS2016Top/> Use of either form in [[pregnancy]] may harm the baby.<ref name=AHFS2016/> Fluorouracil is in the [[antimetabolite]] and [[pyrimidine analog]] families of medications.<ref name=BNF69>{{cite book|title=British national formulary : BNF 69|date=2015|publisher=British Medical Association|isbn=9780857111562|page=590|edition=69}}</ref><ref>{{cite book|last1=Airley|first1=Rachel|title=Cancer Chemotherapy: Basic Science to the Clinic|date=2009|publisher=John Wiley & Sons|isbn=9780470092569|page=76|url=https://books.google.com/books?id=wjjYyYpfiQ8C&pg=PA76|language=en}}</ref> How it works is not entirely clear but believed to involve blocking the action of [[thymidylate synthase]] and thus stopping the production of [[DNA]].<ref name=AHFS2016/>

<!-- History, society and culture -->
Fluorouracil was patented in 1956 and came into medical use in 1962.<ref name=Fis2006>{{cite book|last1=Fischer|first1=Janos|last2=Ganellin|first2=C. Robin|title=Analogue-based Drug Discovery|date=2006|publisher=John Wiley & Sons|isbn=9783527607495|page=511|url=https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA511|language=en}}</ref> It is on the [[World Health Organization's List of Essential Medicines]], the most effective and safe medicines needed in a [[health system]].<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015}}</ref> The wholesale cost in the [[developing world]] is about 1.18 to 3.40 USD per 500&nbsp;mg vial.<ref name=ERC2014>{{cite web|title=Fluorouracil|url=http://erc.msh.org/dmpguide/resultsdetail.cfm?language=english&code=FLU50I&s_year=2014&year=2014&str=50%20mg%2Fml&desc=Fluorouracil&pack=new&frm=AMPOULE&rte=INJ&class_code2=08%2E2%2E&supplement=&class_name=%2808%2E2%2E%29Cytotoxic%20and%20adjuvant%20medicines%3Cbr%3E|website=International Drug Price Indicator Guide|accessdate=8 December 2016}}</ref> In the United Kingdom this amount costs the [[National Health Service|NHS]] about 6.40 pounds.<ref name=BNF69/> In the United States it costs about 18.71 USD.<ref>{{cite web|title=Fluorouracil Prices, Coupons & Patient Assistance Programs - Drugs.com|url=https://www.drugs.com/price-guide/fluorouracil|website=Drugs.com|accessdate=27 June 2017}}</ref>

==Medical uses==
Fluorouracil has been given systemically for [[anal cancer|anal]], [[breast cancer|breast]], [[colorectal cancer|colorectal]], [[oesophageal cancer|oesophageal]], [[stomach cancer|stomach]], [[pancreatic cancer|pancreatic]] and [[skin cancer]]s (especially [[head and neck cancer]]s).<ref name="AMH">{{cite book | editor = Rossi, S | isbn = 978-0-9805790-9-3 | title = Australian Medicines Handbook | place = Adelaide | publisher = The Australian Medicines Handbook Unit Trust | year = 2013 | edition = 2013 }}</ref> It has also been given topically (on the skin) for [[actinic keratoses]], [[skin cancer]]s and [[Bowen's disease]]<ref name = AMH/> and as eye drops for treatment of ocular surface squamous neoplasia.<ref>{{Cite journal|last=Joag|first=Madhura G.|last2=Sise|first2=Adam|last3=Murillo|first3=Juan Carlos|last4=Sayed-Ahmed|first4=Ibrahim Osama|last5=Wong|first5=James R.|last6=Mercado|first6=Carolina|last7=Galor|first7=Anat|last8=Karp|first8=Carol L.|date=2016-03-27|title=Topical 5-Fluorouracil 1% as Primary Treatment for Ocular Surface Squamous Neoplasia|journal=Ophthalmology|doi=10.1016/j.ophtha.2016.02.034|issn=1549-4713|pmid=27030104}}</ref>

==Contraindications==
It is contraindicated in patients that are severely debilitated or in patients with [[bone marrow suppression]] due to either radiotherapy or chemotherapy.<ref name = EMC/> It is likewise contraindicated in pregnant or breastfeeding women.<ref name = EMC/> It should also be avoided in patients that do not have malignant illnesses.<ref name = EMC/>

==Adverse effects==
Adverse effects by frequency include:<ref name = AMH/><ref name = EMC>{{cite web|title=Fluorouracil 50 mg/ml Injection – Summary of Product Characteristics|work=electronic Medicines Compendium|publisher=Hospira UK Ltd|date=24 August 2011|accessdate=24 January 2014|url=http://www.medicines.org.uk/emc/medicine/636/SPC/Fluorouracil++50+mg+ml++Injection/}}</ref><ref name = TGA>{{cite web|title=DBL Fluorouracil Injection BP|work=TGA eBusiness Services|publisher=Hospira Australia Pty Ltd|date=21 June 2012|accessdate=24 January 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02952-3|format=PDF}}</ref><ref name = DM>{{cite web|title=ADRUCIL (fluorouracil) injection [Teva Parenteral Medicines, Inc.]|work=DailyMed|publisher=Teva Parenteral Medicines, Inc.|date=August 2012|accessdate=24 January 2014|url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b90e0da7-f702-4f09-9488-74f2bb20e9ac}}</ref><ref name = MSRT>{{cite web|title=Efudex, Carac (fluorouracil topical) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=24 January 2014|url=http://reference.medscape.com/drug/efudex-carac-fluorouracil-topical-343545#showall}}</ref><ref name = MSRIV>{{cite web|title=Adrucil (fluorouracil) dosing, indications, interactions, adverse effects, and more|work=Medscape Reference|publisher=WebMD|accessdate=24 January 2014|url=http://reference.medscape.com/drug/adrucil-fluorouracil-342092#showall}}</ref><ref>{{cite journal | pmc = 3079190 | pmid=21519541 | doi=10.4306/pi.2011.8.1.71 | volume=8 | title=Onset of Manic Episode during Chemotherapy with 5-Fluorouracil | year=2011 | journal=Psychiatry Investig | pages=71–3 | last1 = Ha | first1 = JH | last2 = Hwang | first2 = DY | last3 = Yu | first3 = J | last4 = Park | first4 = DH | last5 = Ryu | first5 = SH}}</ref><ref>Park H. J., Choi Y. T., Kim I. H., Hah J. C.; A case of reversible dementia associated with depression in a patient on 5-FU or its analogue drugs. J. Korean Neuropsychiatr. Assoc. 1987;30:199–202.</ref><ref>[http://medsfacts.com/study-5FU%28FLUOROURACIL%29-causing-HICCUPS.php MedsFacts meta-analysis covering adverse side effect reports of 5fu(fluorouracil) patients who developed hiccups] at MedsFact, 2013</ref>

===During systemic use===
Common (> 1% frequency):{{colbegin|4}}
* Nausea
* Vomiting
* Diarrhea (see below for details)
* [[Mucositis]]
* Headache
* Myelosuppression (see below for details)
* Alopecia (hair loss)
* Photosensitivity
* [[Hand-foot syndrome]]
* Maculopapular eruption
* Itch
* Cardiotoxicity (see below for details)
* Persistent [[hiccups]]
* Mood disorders (irritability, anxiety, depression)
{{colend}}

Uncommon (0.1–1% frequency):
{{colbegin|4}}
* [[Oesophagitis]]
* GI ulceration and bleeding
* [[Proctitis]]
* Nail disorders
* Vein pigmentation
* Confusion
* Cerebellar syndrome
* [[Encephalopathy]]
* Visual changes
* [[Photophobia]]
* Lacrimation (the expulsion of tears without any emotional or physiologic reason)
{{colend}}

Rare (< 0.1% frequency):
* [[Anaphylaxis]] 
* Allergic reactions
* Fever without signs of infection

Diarrhea is severe and may be dose-limiting and is exacerbated by co-treatment with [[calcium folinate]].<ref name = AMH/> [[Neutropenia]] tends to peak about 9–14 days after beginning treatment.<ref name = AMH/> [[Thrombocytopenia]] tends to peak about 7–17 days after the beginning of treatment and tends to recover about 10 days after its peak.<ref name = AMH/> [[Cardiotoxicity]] is a fairly common side effect, but usually this cardiotoxicity is just [[angina]] or symptoms associated with [[Coronary vasospasm|coronary artery spasm]], but in about 0.55% of those receiving the drug will develop life-threatening cardiotoxicity.<ref name="MD">{{cite web|title=Fluorouracil: Martindale: The Complete Drug Reference|date=9 January 2017|url=https://www.medicinescomplete.com/mc/martindale/current/1836-x.htm|accessdate=14 August 2017|editor=Brayfield, A|publisher=Pharmaceutical Press|website=MedicinesComplete|location=London, UK}}</ref> Life-threatening cardiotoxicity includes: [[arrhythmias]], [[ventricular tachycardia]] and [[cardiac arrest]], secondary to transmural ischaemia.<ref name="MD"/>

===During topical use===
<ref name = AMH/><ref name = MSRT/>

Common (> 1% frequency):
{{colbegin|4}}
* Local pain
* Itchiness
* Burning
* Stinging
* Crusting
* Weeping
* Dermatitis
* Photosensitivity
{{colend}}

Uncommon (0.1–1% frequency):
* hyper- or hypopigmentation
* Scarring

===Neurological damage===
5-FU injection and topical application, even in small doses, cause both acute [[central nervous system]] (CNS) damage and progressively worsening delayed degeneration of the CNS in mice. This latter effect is caused by 5-FU-induced damage to the [[oligodendrocytes]] that produce the insulating [[myelin]] sheaths.
<ref>{{cite web|url=http://www.urmc.rochester.edu/news/story/index.cfm?id=1963|title=Researchers Detail Chemotherapy’s Damage to the Brain}}</ref>
<ref>{{cite web|url=http://www.urmc.rochester.edu/news/story/index.cfm?id=1312|title=Common Cancer Treatments Toxic to Healthy Brain Cells}}</ref>

The United States package insert warns that [[acute cerebellar syndrome]] has been observed following injection of fluorouracil and may persist after cessation of treatment. Symptoms include [[ataxia]], [[nystagmus]], and [[dysmetria]].<ref>{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0794add-67a7-4308-93e9-f889472716cc |title=Adrucil (Fluorouracil) Injection [TEVA Parenteral Medicines, Inc.] |format= |work= |accessdate=}}</ref>

==Potential overdose==
There is very little difference between the minimum effective dose and maximum tolerated dose of 5-FU, and the drug exhibits marked individual pharmacokinetic variability.<ref name="dose monitoring">{{cite journal|author1=Gamelin, E.|author2=Boisdron-Celle, M.|title=Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer—status of the art|journal=Critical Reviews in Oncology/Hematology|year=1999|volume=30|issue=1|pages=71–79|doi=10.1016/s1040-8428(98)00036-5}}</ref><ref name="dosing strategies">{{cite journal|author1=Felici A.|author2=J. Verweij|author3=Sparreboom A.|title=Dosing strategies for anticancer drugs: the good, the bad and body-surface area|journal=Eur J Cancer|year=2002|volume=38|issue=13|pages=1677–84|doi=10.1016/s0959-8049(02)00151-x}}</ref><ref name="role of body">{{cite journal|author1=Baker S. D.|author2=Verweij J. |author3=Rowinsky E. K.|author4=Donehower R. C.|author5=Schellens J. H.|author6=Grochow L. B.|author7=Sparreboom A.|title=Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001|journal=J. Natl Cancer Inst|year=2002|volume=94|issue=24|pages=1883–8|doi=10.1093/jnci/94.24.1883}}</ref> Therefore, an identical dose of 5-FU may result in a therapeutic response with acceptable toxicity in some patients and unacceptable and possibly life-threatening toxicity in others.<ref name="dose monitoring"/> Both overdosing and underdosing are of concern with 5-FU, although several studies have shown that the majority of colorectal cancer patients treated with 5-FU are underdosed based on today's dosing standard, body surface area (BSA).<ref name="dose adjustment">{{cite journal|author1=Capitain O.|author2=Asevoaia A.|author3=Boisdron-Celle M.|author4=Poirier A. L.|author5=Morel A.|author6=Gamelin E.|title=Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study|journal=Clin. Colorectal Cancer|year=2012|volume=11|issue=4|pages=263–267|doi=10.1016/j.clcc.2012.05.004}}</ref><ref name="body surface area">{{cite journal|author1=Saam, J|author2=Critchfield G. C.|author3=Hamilton S. A.|author4=Roa B. B.|author5=Wenstrup R. J.|author6=Kaldate R. R.|title=Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens|journal=Clin Colorectal Cancer|year=2011|volume=10|issue=3|pages=203–6|doi=10.1016/j.clcc.2011.03.015}}</ref><ref name="multicenter evaluation">{{cite journal|author1=Beumer J. H.|author2=Boisdron-Celle M.|author3=Clarke W.|author4=Courtney J. B.|author5=Egorin M. J.|author6=Gamelin E|author7=Harney R. L.|author8=Hammett-Stabler C|author9=Lepp S.|author10=Li Y.|author11=Lundell G. D.|author12=McMillin G.|author13=Milano G.|author14=Salamone S. J.|title=Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer|journal=Ther. Drug Monit.|year=2009|volume=31|issue=6|pages=688–94}}</ref><ref>{{cite journal|author1=Goldberg R. M.|author2=Rothenberg M. L.|author3=Van Cutsem E.|author4=Benson A. B. 3rd|author5=Blanke C. D.|author6=Diasio R. B.|author7=Grothey A.|author8=Lenz H. J.|author9=Meropol N. J.|author10=Ramanathan R. K.|author11=Becerra C. H.|author12=Wickham R.|author13=Armstrong D.|author14=Viele C.|title=The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer|journal=The Oncologist|year=2007|volume=12|pages=38–50|doi=10.1634/theoncologist.12-1-38}}</ref> The limitations of BSA-based dosing prevent oncologists from being able to accurately titer the dosage of 5-FU for the majority of individual patients, which results in sub-optimal treatment efficacy or excessive toxicity.<ref name="dose adjustment"/><ref name="body surface area"/>

Numerous studies have found significant relationships between concentrations of 5-FU in blood plasma and both desirable or undesirable effects on patients.<ref>{{cite journal|author1=Ploylearmsaeng, S.-a.|author2=Fuhr U.|author3=Jetter A.|title=How may Anticancer Chemotherapy with Fluorouracil be Individualised?|journal=Clin Pharmacokinet|year=2006|volume=45|issue=6|pages=567–92|doi=10.2165/00003088-200645060-00002}}</ref><ref>{{cite journal|author1=van Kuilenburg, A. B.|author2=Maring J. G.|title=Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients|journal=Pharmacogenomics|year=2013|volume=14|issue=7|pages=799–811|doi=10.2217/pgs.13.54}}</ref> Studies have also shown that dosing based on the concentration of 5-FU in plasma can greatly increase desirable outcomes while minimizing negative side effects of 5-FU therapy.<ref name="dose adjustment"/><ref name="individual fluorouracil">{{cite journal|author1=Gamelin E. C.|author2=Delva R.|author3=Jacob J.|author4=Merrouche Y|author5=Raoul J. L.|author6=Pezet D.|author7=Dorval E.|author8=Piot G.|author9=Morel A.|author10=Boisdron-Celle M.|title= Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer|journal=J. Clin. Oncol.|year=2008|volume=26|issue=13|pages=2099–2105|doi=10.1200/jco.2007.13.3934|pmid=18445839}}</ref> One such test that has been shown to successfully monitor 5-FU plasma levels and which "may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies" is the My5-FU test.<ref name="multicenter evaluation"/><ref>{{cite web|url=http://Mycaretests.com|title=Customizing Chemotherapy for Better Cancer Care|publisher=MyCare Diagnostics}}</ref><ref>{{cite web|url=http://bettercancercare.com|title=A Brief History of BSA Dosing|publisher=MyCare Diagnostics}}</ref>

==Interactions==
Its use should be avoided in patients receiving drugs known to modulate [[dihydropyrimidine dehydrogenase]] (such as the antiviral drug [[sorivudine]]).<ref name = EMC/> It may also increase the INR and prothrombin times in patients on [[warfarin]].<ref name = EMC/> Fluorouracil's efficacy is decreased when used alongside [[allopurinol]], which can be used to decrease fluorouracil induced stomatitis through use of allopurinol mouthwash.<ref name="pmid8192112">{{cite journal |vauthors=Porta C, Moroni M, Nastasi G |title=Allopurinol mouthwashes in the treatment of 5-fluorouracil-induced stomatitis |journal=[[Am. J. Clin. Oncol.]] |volume=17 |issue=3 |pages=246–7 |year=1994 |pmid=8192112 |doi= 10.1097/00000421-199406000-00014|url=}}</ref>

==Pharmacology==

===Pharmacogenetics===

The [[dihydropyrimidine dehydrogenase]] (DPD) enzyme is responsible for the detoxifying metabolism of fluoropyrimidines, a class of drugs that includes 5-fluorouracil, [[capecitabine]], and [[tegafur]].<ref name="pmid23988873">{{cite journal|last1=Caudle|first1=KE|last2=Thorn|first2=CF|last3=Klein|first3=TE|last4=Swen|first4=JJ|last5=McLeod|first5=HL|last6=Diasio|first6=RB|last7=Schwab|first7=M|title=Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.|journal=Clinical pharmacology and therapeutics|date=December 2013|volume=94|issue=6|pages=640–5|doi=10.1038/clpt.2013.172|pmid=23988873|pmc=3831181}}</ref> [[Genetic variation]]s within the DPD gene (''DPYD'') can lead to reduced or absent DPD activity, and individuals who are [[heterozygous]] or [[homozygous]] for these variations may have partial or complete [[DPD deficiency]]; an estimated 0.2% of individuals have complete [[DPD deficiency]].<ref name="pmid23988873"/><ref name="pmid21919607">{{cite journal|last1=Amstutz|first1=U|last2=Froehlich|first2=TK|last3=Largiadèr|first3=CR|title=Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity.|journal=Pharmacogenomics|date=September 2011|volume=12|issue=9|pages=1321–36|pmid=21919607|doi=10.2217/pgs.11.72}}</ref> Those with partial or complete DPD deficiency have a significantly increased risk of severe or even fatal drug toxicities when treated with fluoropyrimidines; examples of toxicities include [[myelosuppression]], [[neurotoxicity]] and [[hand-foot syndrome]].<ref name="pmid23988873"/><ref name="pmid21919607"/>

===Mechanism of action===
5-FU acts in several ways, but principally as a [[thymidylate synthase inhibitor|thymidylate synthase (TS) inhibitor]]. Interrupting the action of this enzyme blocks synthesis of the pyrimidine [[thymidine]], which is a [[nucleoside]] required for [[DNA replication]]. [[Thymidylate synthase]] methylates deoxyuridine monophosphate (dUMP) to form [[thymidine monophosphate]] (dTMP). Administration of 5-FU causes a scarcity in dTMP, so rapidly dividing cancerous cells undergo cell death via [[thymineless death]].<ref>{{cite journal |author1=Longley D. B. |author2=Harkin D. P. |author3=Johnston P. G. |title=5-fluorouracil: mechanisms of action and clinical strategies |journal=Nat. Rev. Cancer |volume=3 |issue=5 |pages=330–8 |date=May 2003|pmid=12724731|doi=10.1038/nrc1074|url=http://www.nature.com/nrc/journal/v3/n5/full/nrc1074.html}}</ref> Calcium folinate provides an exogenous source of reduced folinates and hence stabilises the 5-FU-TS complex, hence enhancing 5-FU's cytotoxicity.<ref>{{cite journal|title=5-Fluorouracil derivatives: a patent review|journal=Expert Opinion on Therapeutic Patents|date=February 2012|volume=22|issue=2|pages=107–123|author1=Álvarez, P. |author2=Marchal, J. A. |author3=Boulaiz, H. |author4=Carrillo, E. |author5=Vélez, C. |author6=Rodríguez-Serrano, F. |author7=Melguizo, C. |author8=Prados, J. |author9=Madeddu, R. |author10=Aranega, A. |doi=10.1517/13543776.2012.661413|pmid=22329541}}</ref>

== History ==
In 1954 Abraham Cantarow and Karl Paschkis found liver tumors absorbed radioactive [[uracil]] more readily than normal liver cells. [[Charles Heidelberger]], who had earlier found that fluorine in [[fluoroacetic acid]] inhibited a vital enzyme, asked Robert Duschinsky and Robert Schnitzer at [[Hoffman-La Roche]] to synthesize fluorouracil.<ref>Sneader W. (2005). ''Drug Discovery'', p. 255.</ref> Some credit Heidelberger and Duschinsky with the discovery that 5-fluorouracil markedly inhibited tumors in mice.<ref>{{cite journal |author=Cohen, Seymour |title=50 years ago in cell biology: A virologist recalls his work on cell growth inhibition |journal=The Scientist |date=30 January 2008 |url=http://www.the-scientist.com/news/display/54259/}}</ref> The original 1957 report<ref>{{cite journal |author=Chu E |title=Ode to 5-Fluorouracil |journal=Clinical Colorectal Cancer |volume=6 |issue=9 |pages=609 |date=September 2007 |doi=10.3816/CCC.2007.n.029 |url=http://cigjournals.metapress.com/content/b464v2u31594jj28/}}</ref><ref>National Academy of Sciences, Biographical Memoirs,80:135</ref> in ''Nature'' has Heidelberger as lead author, along with N. K. Chaudhuri, Peter Danneberg, Dorothy Mooren, Louis Griesbach, Robert Duschinsky, R. J. Schnitzer, E. Pleven, and J. Scheiner.<ref>{{cite journal |author1=Heidelberger C. |author2=Chaudhuri N. K. |author3=Danneberg P. |title=Fluorinated pyrimidines, a new class of tumour-inhibitory compounds |journal=Nature |volume=179 |issue=4561 |pages=663–6|date=March 1957|pmid=13418758 |doi=10.1038/179663a0 |display-authors=etal}}</ref>

==Natural analogues==
In 2003 it was discovered that a closely related compound{{clarify|date=June 2016}} is produced by a marine sponge, ''[[Phakellia fusca]]''. This is significant because fluorine-containing organic compounds exist only rarely in nature, and  also because manmade anticancer drugs are not frequently [[autopharmacology|found to have analogues in nature]].<ref>{{Cite journal|last=Xu|first=Xiao-Hua|last2=Yao|first2=Guang-Min|last3=Li|first3=Yan-Ming|last4=Lu|first4=Jian-Hua|last5=Lin|first5=Chang-Jiang|last6=Wang|first6=Xin|last7=Kong|first7=Chui-Hua|date=2003-02-01|title=5-Fluorouracil derivatives from the sponge Phakellia fusca|journal=Journal of Natural Products|volume=66|issue=2|pages=285–288|doi=10.1021/np020034f|issn=0163-3864|pmid=12608868}}</ref>

== Interactive pathway map ==
{{FluoropyrimidineActivity WP1601}}

==Names==
The name "fluorouracil" is the [[international nonproprietary name|INN]], [[United States Adopted Name|USAN]], [[United States Pharmacopeia|USP]] name, and [[British Approved Name|BAN]]. The form "5-fluorouracil" is often used; it shows that there is a fluorine atom on the 5th carbon of a [[uracil]] ring.

==References==
{{reflist|32em}}

== External links ==
* [https://cjon.ons.org/cjon/18/5/5-fluorouracil-toxicity-and-dihydropyrimidine-dehydrogenase-enzyme-implications-practice]

{{Chemotherapeutic agents}}

[[Category:Nucleobases]]
[[Category:Organofluorides]]
[[Category:Pyrimidinediones]]
[[Category:Pyrimidine antagonists]]
[[Category:Thymidylate synthase inhibitors]]
[[Category:World Health Organization essential medicines]]
[[Category:RTT]]
[[Category:Uracil derivatives]]